Recent Price Movement and Market Context
On the day the new low was recorded, Mankind Pharma’s stock touched an intraday low of Rs.2029.35, down 2.55% from the previous close. The stock’s day change was -1.33%, moving in line with the sector’s performance. Over the last three sessions, the stock has consistently declined, reflecting a cumulative negative return of 4.87%. Notably, the share price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the Sensex opened flat but turned negative, trading at 83,228.21 points, down 0.1% and approximately 3.52% below its 52-week high of 86,159.02. While the benchmark index remains relatively strong, Mankind Pharma’s underperformance is pronounced, with the stock’s one-year return at -17.21% compared to the Sensex’s positive 6.62% over the same period.
Financial Performance and Valuation Metrics
Mankind Pharma’s recent financial results have been largely flat, with no significant growth reported in the December 2025 half-year period. The company’s Return on Capital Employed (ROCE) for the half-year stands at 12.33%, the lowest recorded in recent periods, indicating a decline in capital efficiency. This contrasts with the company’s longer-term ROCE of 25.78%, which remains relatively high and reflects management’s ability to generate returns on invested capital over time.
The Debtors Turnover Ratio for the half-year is also at a low of 7.13 times, suggesting slower collection cycles compared to previous periods. This metric is critical in assessing working capital management and cash flow health.
Valuation-wise, Mankind Pharma is trading at an enterprise value to capital employed ratio of 4.4, which is considered expensive relative to its peers’ historical averages. The stock’s price-to-earnings multiple, implied by the ROCE of 11.7, suggests a premium valuation despite the recent earnings contraction. Over the past year, profits have declined by 8.1%, further weighing on investor sentiment.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Long-Term and Sectoral Performance
Over the last three years, Mankind Pharma has underperformed the BSE500 index, continuing a trend of below-par returns in both the near and long term. The stock’s 52-week high was Rs.2726.75, indicating a significant decline of approximately 25.6% from that peak to the current 52-week low. This performance gap is notable given the Pharmaceuticals & Biotechnology sector’s overall resilience and growth prospects.
Despite the recent setbacks, the company has demonstrated healthy long-term growth in net sales and operating profit, with annual growth rates of 18.21% and 18.72% respectively. These figures reflect sustained demand and operational scale within the sector, even as short-term pressures have impacted profitability and share price.
Balance Sheet Strength and Institutional Support
Mankind Pharma maintains a strong balance sheet, with a low Debt to EBITDA ratio of 0.54 times, indicating a robust capacity to service debt obligations. This financial prudence provides a degree of stability amid market fluctuations.
Institutional investors hold a significant 24.59% stake in the company, underscoring confidence from entities with extensive analytical resources. Such holdings often reflect a thorough assessment of fundamentals and long-term prospects, even when short-term price movements are unfavourable.
Holding Mankind Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Mojo Score and Analyst Ratings
Mankind Pharma’s current Mojo Score stands at 38.0, categorised as a Sell grade. This represents a downgrade from the previous Hold rating, which was revised on 19 Nov 2025. The downgrade reflects the combination of flat recent results, declining profitability, and valuation concerns. The company’s market capitalisation grade is rated at 1, indicating a relatively small market cap compared to larger peers in the Pharmaceuticals & Biotechnology sector.
The downgrade and low Mojo Score highlight the challenges faced by the stock in maintaining investor confidence amid a competitive and evolving industry landscape.
Summary of Key Metrics
To summarise, Mankind Pharma Ltd’s stock has reached a 52-week low of Rs.2029.35 after a sustained period of price decline. The stock’s underperformance relative to the Sensex and sector peers is underpinned by flat financial results, reduced capital efficiency, and a premium valuation despite shrinking profits. However, the company’s strong management efficiency, low leverage, and healthy long-term sales growth provide a foundation of operational strength.
Investors and market participants will continue to monitor these metrics closely as the stock navigates this challenging phase within the broader Pharmaceuticals & Biotechnology sector.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
